Skip to main content

Adam C. Lenain

Member

[email protected]

+1.858.314.1878

Share:

Adam routinely assists public and private life sciences and technology companies navigate complex legal and business issues throughout the corporate life cycle.  With a practical and creative focus on his clients’ intended business results, he often functions as an outside general counsel and is regularly consulted by management teams for guidance on strategic matters.  

Adam has over twenty years of experience representing clients in angel and venture capital financings, public offerings, reverse mergers, PIPEs, mergers and acquisitions, SEC Compliance, and complex commercial transactions.  He regularly represents both buyers and sellers in mergers and acquisitions as well as corporations and limited liability companies with respect to financings and general corporate issues that arise throughout the corporate life cycle--from formation to exit.

While an undergraduate at Yale, Adam played both football and baseball.

Experience

Recent Representative Transactions

For Evofem Biosciences, Inc.:

  • $80,000,000 common stock PIPE with Woodford Investment Management and PDL Biopharma, Inc.

  • $100,000,000 public offering underwritten by Morgan Stanley

  • $50,000,000 ATM managed by Piper Sandler & Co.

  • Merger with Neothetics, Inc. (stock for stock)

  • $25,000,000 senior secured convertible note PIPE with Baker Bros. 

  • $1,000,000 preferred stock PIPE with Keystone Capital

  • $25,000,000 unsecured convertible note PIPE with Adjuvant Global Health Technology Fund

  • $13,500,000 registered direct offering conducted on a best efforts basis by Piper Sandler & Co.

  • $24,000,000 public offering underwritten by H.C. Wainwright

For GRI Bio, Inc.:

  • $12,500,000 common stock PIPE with warrants with Altium Growth Fund

  • Merger with Vallon Pharmaceuticals (stock for stock)

  • $5,000,000 public offering of common stock, pre-funded warrants and warrants to purchase preferred stock underwritten by AGP

  • ATM managed by H.C. Wainwright

For Wickr, Inc.:

  • $8,300,000 Series B-2 preferred stock financing led by Alsop Louie and Breyer Capital

  • $5,000,000 Series C preferred stock financing led by Merlin International Inc.

  • $5,000,000 venture debt financing with SVB

  • Merger with Net Power and Light (stock for stock)

Other Recent Financing Transactions:

  • $3,000,000 convertible note financing of Avenzoar Pharmaceuticals led by Ally Capital Holdings

  • $2,000,000 Series A Preferred Stock financing of Curvo Labs, Inc. led by Snake Run Capital and Indiana 21st Century Fund

  • $18,000,000 Series A Preferred Stock financing of FAScinate Therapeutics, Inc. led by Kainos Medicine and TWI IP Commercialization Fund and The Wells Doctors Healthcare Fund

  • $2,000,000 convertible note financing of Hollywood Glow Girls

  • $2,000,000 convertible note financing of Injury AI, Inc.

  • $1,000,000 convertible note financing of Regencor, Inc.

Other Recent M&A Transactions:

  • Curvo Labs, Inc. stock purchase of Mendenhal Associates (cash consideration)

  • Curvo Labs, Inc. stock purchase of Strategic Healthcare (cash consideration)

  • Evofem, Inc.’s asset purchase of Cosmederm, Inc. (cash consideration)

  • Encore Sports asset sale to Decade Sports (cash consideration)

  • Evanoa Bioscience, Inc. asset acquisition of Evolugate LLC (stock consideration)

  • Evanoa Bioscience, Inc. asset acquisition of Biotork LLC (stock consideration)

Commercial Agreements:

  • License Agreement between NeptuneBio, Inc. and Mayo Clinic

  • Development Agreement between Evanoa Bioscience and Aldevron

  • Multiple Consulting Agreement and Employment Agreements

  • License Agreement between Avenzoar Pharmaceuticals and Cedars-Sinai

  • Development Agreement between Biotork LLC and Lallemand/Mascoma

  • Joint Venture Agreement between Caelum Resources, Inc. and CFS Holdings Private Limited Zimbabwe

  • Multiple SAAS Agreements for Curvo Labs, Inc. and Wickr Inc.

  • License Agreement between FAScinate Therapeutics and Kainos Medicine

  • License Agreement between InVaMet and Virginia Commonwealth

  • License Agreement between ILCT and Virginia Commonwealth

 

Read less

viewpoints

Life Sciences Newsletter — September 2021

September 1, 2021 | Article | By Adam Lenain, William Whelan, Jonathan L. Kravetz, Terri Shieh-Newton

This edition covers return-to-work challenges, insight on patenting AI innovations, FDA guidance on medical devices, transactional and IP activity in the life sciences, and recent Mintz work for life sciences clients.
Read more
Read less

News & Press

Press Release Thumbnail Mintz

187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.

Press Release Thumbnail Mintz

187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.

Press Release Thumbnail Mintz

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail Mintz

Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.

News Thumbnail Mintz
Adam Lenain, a member of Mintz’s San Diego office, counsels technology companies, both public and private, on matters including mergers and acquisitions, licensing and collaborations, and general corporate and securities issues.
Adam Lenain, a Member in Mintz’s San Diego office, counsels technology companies, both public and private, on matters including mergers and acquisitions, licensing and collaborations, and general corporate and securities issues.
Continuing to expand its renowned life sciences platform, Mintz announced the addition of Adam Lenain as a Member in the firm’s Corporate Practice, based in San Diego.
Read less

Recognition & Awards

  • Best Lawyers in America: San Diego - Biotechnology and Life Sciences Practice Lawyer of the Year (2025)


     

  • Best Lawyers in America: Corporate Law (2021 – 2025); Biotechnology and Life Sciences Practice (2023-2025)

  • The Legal 500 United States: M&A: Middle-Market (2024)

  • San Diego Business Journal Leaders in Law Winner (2020)

  • Order of the Coif

  • University of San Diego Law Review editor

  • University of San Diego School of Law merit scholarship recipient

Read less

Involvement

  • Member, State Bar of California
  • Member, San Diego County Bar Association
Read less